Breast Cancer

The FDA approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.

The United States Food and Drug Administration recently approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.

This continuing education activity addresses the factors that increase and decrease a woman's risk for breast cancer, and includes information for pharmacists to help provide evidence-based counseling on preventative measures.

The FDA approved Genentech, Inc's pertuzumab injection (Perjeta) for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Girls who received mantle radiation for childhood cancer were found to be at elevated risk for secondary breast cancer later in life.

Intravenous bisphosphonates, often used to treat metastases and bone pain in breast cancer patients, are now being used by clinicians for osteoporosis in these patients—pharmacists need to recommend appropriate screening and treatment.